FB

Finedix BV

Description

Finedix BV

Investor Profile

Finedix BV has backed more than 2 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series D, Series B rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Biopharma, Clinical Trials.

Stage Focus

  • Series D (50%)
  • Series B (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Biopharma
  • Clinical Trials
  • Health Care
  • Medical Device
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Finedix BV frequently co-invest with?

BV
North America, California, United States, Foster City
Co-Investments: 1
InterWest Partners
North America, California, United States, Menlo Park
Co-Investments: 1
Bain Capital Life Sciences
North America, Massachusetts, United States, Boston
Co-Investments: 1
JAFCO Asia
Asia, Central Region, Singapore, Singapore
Co-Investments: 1
BioVeda Capital
Asia, Central Region, Singapore, Singapore
Co-Investments: 1
Care Capital
North America, New Jersey, United States, Princeton
Co-Investments: 1
Co-Investments: 1
Alta Partners
North America, Mississippi, United States, Jackson
Co-Investments: 1
HealthCap
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 1
Forward Ventures
North America, California, United States, San Diego
Co-Investments: 1

What are some of recent deals done by Finedix BV?

Dynavax Technologies

Berkeley, California, United States

Dynavax Technologies is a biopharmaceutical company discovering and developing novel products to prevent and treat infectious diseases.

BiopharmaBiotechnologyClinical TrialsHealth CareMedical Device
Series DApr 25, 2002
Amount Raised: $34,800,000
ConjuChem

Los Angeles, California, United States

ConjuChem creates novel, next-generation medicines using unique, long-acting therapeutic peptides.

Biotechnology
Series BAug 1, 1999
Amount Raised: $8,500,000